retatrutide phase 2 trial type 2 diabetes weight loss 2024 Lilly's triple agonist, retatrutide, successful in two additional 3 obesity trials, delivering significant improvements in and A1C Lilly's triple agonist achieves 16.8%

All of the dynamics around GLP-1s, compounding shortage workarounds, and potential for DTC telehealth fallout I described last August seem to be playing out in 2025

And we need to recognize that if something seems too good to be true, it probably is

These combination protocols explore potential complementary effects involving: Lean-mass maintenance Recovery support Exercise adaptation Tissue-repair pathways Recovery physiology during caloric restriction With Growth HormoneRelated Research Peptides Retatrutide is sometimes researched alongside peptides such as: Tesamorelin Ipamorelin CJC-1295 These combinations are explored in metabolic and body-composition research involving: Fat oxidation Recovery signaling Lean-mass preservation Recovery support during weight-management protocols With Mitochondrial & Metabolic Research Compounds Retatrutide is commonly investigated alongside compounds involved in: Mitochondrial function Cellular energy production Fat metabolism Glucose regulation Metabolic efficiency Researchers explore whether these combinations may support broader metabolic and energy-utilization pathways

In the head-to-head SURMOUNT trial, funded by drug manufacturer Eli Lilly, people who took tirzepatide lost more weight than those who took semaglutide (Ozempic)